(Q35001270)

5 August 2017

1 reference

title

Current progress in the pharmacological therapy of fibromyalgia (English)

1 reference

5 August 2017

0 references

Srinivas G Rao

1

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

Expert Opinion on Investigational Drugs

5 August 2017

published in

1 reference

5 August 2017

volume

18

1 reference

5 August 2017

issue

10

1 reference

5 August 2017

page(s)

1479-1493

1 reference

The prevalence and characteristics of fibromyalgia in the general population.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Update on fibromyalgia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Fibromyalgia: should the treatment paradigm be monotherapy or combination pharmacotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Hypothalamic-pituitary-adrenal and autonomic nervous system functioning in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: new concepts in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Pharmacological treatments of fibromyalgia: do complex conditions need complex therapies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Fibromyalgia patients show an abnormal dopamine response to pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

The promise of substance P inhibitors in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Treatment of fibromyalgia and its symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Biology and therapy of fibromyalgia. Stress, the stress response system, and fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Sleep in fibromyalgia patients: subjective and objective findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Modulators in concert for cognition: modulator interactions in the prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Allelic Variation of Human Serotonin Transporter Gene Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5- HTTLPR) polymorphism, and relationship to anxiety-related personality traits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Catechol-O-methyltransferase gene haplotypes in Mexican and Spanish patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Fibromyalgia: update on mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

OMERACT: an international initiative to improve outcome measurement in rheumatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

The PTPN22*C1858T functional polymorphism is associated with susceptibility to inflammatory polyarthritis but neither this nor other variants spanning the gene is associated with disease outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

The neuropharmacology of centrally-acting analgesic medications in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Descending control of pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

A six-month randomized controlled trial of exercise and pyridostigmine in the treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

An open-label study of quetiapine in the treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Nabilone for the treatment of pain in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Fibromyalgia symptoms relieved by flupirtine: an open-label case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

gamma-Hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients. A double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Zopiclone in the treatment of sleep abnormalities in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

An open clinical trial of venlafaxine treatment of fibromyalgia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Venlafaxine Treatment of Fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Alpha2-adrenergic receptor agonists as analgesics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

New treatment options using 5-HT3 receptor antagonists in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Patients treated by tegaserod for irritable bowel syndrome with constipation showed significant improvement in fibromyalgia symptoms. A pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Growth hormone perturbations in fibromyalgia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Effect of tachykinin receptor antagonists in experimental neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Modafinil in fibromyalgia treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

The classification of fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

The Xyrem risk management program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

An elephant among us: the role of dopamine in the pathophysiology of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

The genetics of fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903203771

10.1517/13543780903203771

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference